Medicare Enrolled
Dr. Charles Yen, M.D.
Optician · Houston, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Yen from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Yen? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Yen
Dr. Charles Yen is an optician in Houston, TX, with 20 years in practice. Based on federal Medicare data, Dr. Yen performed 28,466 Medicare services across 810 unique beneficiaries.
Between the years covered by Open Payments, Dr. Yen received a total of $40,808 from 106 pharmaceutical and/or device companies across 1661 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in optician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Yen is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice▲ Top 2% volume in TX$ $40,808 industry payments
Medicare Practice Summary
Medicare Utilization ↗28,466
Medicare services
Top 2% in TX for optician
810
Unique beneficiaries
$8
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~1,423 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) | 21,000 | $1 | $3 |
| Dexamethasone injection (steroid) | 2,196 | $0 | $0 |
| Contrast dye for imaging (iodine-based) | 2,100 | $0 | $0 |
| Anti-nausea injection (Aloxi/palonosetron) | 760 | $1 | $7 |
| Office visit, established patient (30-39 min) | 701 | $93 | $345 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 451 | $23 | $82 |
| Administration of chemotherapy into vein, 1 hour or less | 261 | $105 | $375 |
| Administration of chemotherapy into vein, each additional hour | 141 | $23 | $80 |
| Hospital follow-up visit, high complexity | 128 | $96 | $301 |
| Administration of additional new drug or substance into vein, 1 hour or less | 98 | $52 | $183 |
| Drug injection, under skin or into muscle | 94 | $11 | $39 |
| Injection, diphenhydramine hcl, up to 50 mg | 92 | $1 | $3 |
| Office visit, established patient (20-29 min) | 85 | $70 | $251 |
| Irrigation of implanted venous access drug delivery device | 71 | $20 | $73 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 63 | $50 | $179 |
| New patient office visit (45-59 min) | 55 | $127 | $448 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 36 | $1,182 | $5,182 |
| Initial hospital admission, high complexity | 27 | $140 | $504 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 27 | $109 | $295 |
| Office visit, established patient, complex (40-54 min) | 23 | $145 | $462 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 22 | $19 | $62 |
| Ct scan of abdomen and pelvis before and after contrast | 18 | $187 | $910 |
| Ct scan of chest with contrast | 17 | $48 | $433 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
75.6% high complexity
20.1% medium
4.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$40,808
Total received (2018-2024)
Avg $5,830/year across 7 years
Top 6% in TX for optician
106
Companies
1,661
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$30,590 (75.0%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$9,253 (22.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$965 (2.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$10,021
2023$7,564
2022$5,317
2021$6,860
2020$2,153
2019$6,203
2018$2,689
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$4,311
Karyopharm Therapeutics Inc.
$3,287
Janssen Biotech, Inc.
$2,907
Janssen Scientific Affairs, LLC
$2,366
Novartis Pharmaceuticals Corporation
$2,270
Celgene Corporation
$2,016
E.R. Squibb & Sons, L.L.C.
$1,593
PFIZER INC.
$1,573
Amgen Inc.
$1,506
GlaxoSmithKline, LLC.
$1,472
GENZYME CORPORATION
$1,170
Astellas Pharma US Inc
$1,015
Takeda Pharmaceuticals U.S.A., Inc.
$868
Daiichi Sankyo Inc.
$835
Seagen Inc.
$695
Incyte Corporation
$672
Eisai Inc.
$656
Genentech USA, Inc.
$634
Lilly USA, LLC
$613
Merck Sharp & Dohme Corporation
$609
Gilead Sciences, Inc.
$595
Pharmacyclics LLC, An AbbVie Company
$480
SOBI, INC
$398
Merck Sharp & Dohme LLC
$390
ABBVIE INC.
$366
PharmaEssentia USA Corporation
$342
BeiGene USA, Inc.
$324
Ipsen Biopharmaceuticals, Inc
$298
Boehringer Ingelheim Pharmaceuticals, Inc.
$274
COMSORT, Inc
$250
Myriad Genetic Laboratories, Inc.
$242
Regeneron Healthcare Solutions, Inc.
$225
TAIHO ONCOLOGY, INC.
$220
AVEO Pharmaceuticals, Inc.
$210
Dendreon Pharmaceuticals LLC
$198
Pharmacosmos Therapeutics Inc.
$182
Rigel Pharmaceuticals, Inc.
$178
Kite Pharma, Inc.
$172
Blueprint Medicines Corporation
$170
TerSera Therapeutics LLC
$156
EISAI INC.
$152
MorphoSys, US Inc.
$141
ARRAY BIOPHARMA INC
$140
Pharmacyclics LLC, an AbbVie Company
$126
EMD Serono, Inc.
$123
Verastem, Inc.
$121
Coherus Biosciences Inc.
$119
Sobi, Inc
$119
Janssen Pharmaceuticals, Inc
$112
Taiho Oncology, Inc.
$110
Bayer Healthcare Pharmaceuticals Inc.
$106
CTI BioPharma Corp.
$104
Agios Pharmaceuticals, Inc.
$103
Dova Pharmaceuticals
$101
Bayer HealthCare Pharmaceuticals Inc.
$100
SANOFI-AVENTIS U.S. LLC
$100
Alexion Pharmaceuticals, Inc.
$96
Foundation Medicine, Inc.
$96
Adaptive Biotechnologies Corporation
$94
Mirati Therapeutics, Inc.
$90
Stemline Therapeutics Inc.
$89
Pharming Healthcare, Inc.
$86
Tempus AI, Inc
$82
Teva Pharmaceuticals USA, Inc.
$78
Puma Biotechnology, Inc.
$77
Servier Pharmaceuticals LLC
$77
Spectrum Pharmaceuticals Inc.
$76
Octapharma USA, Inc.
$66
SpringWorks Therapeutics, Inc.
$65
Global Blood Therapeutics, Inc.
$64
Clovis Oncology, Inc.
$62
Sirtex Medical Inc
$54
AbbVie Inc.
$53
Deciphera Pharmaceuticals Inc.
$50
PUMA BIOTECHNOLOGY, INC.
$47
Boston Scientific Corporation
$45
G1 Therapeutics, Inc.
$44
TESARO, Inc.
$41
ADC Therapeutics America, Inc.
$40
Genentech, Inc.
$38
Immunocore Limited
$37
Epizyme, Inc.,
$35
Myovant Sciences Inc.
$34
Aveo Pharmaceuticals, Inc.
$32
Novo Nordisk Inc
$31
JAZZ PHARMACEUTICALS INC.
$31
Amneal Pharmaceuticals LLC
$27
Aurobindo Pharma USA, Inc.
$24
Heron Therapeutics, Inc.
$24
MEDIVATION FIELD SOLUTIONS LLC
$23
Horizon Pharma plc
$22
Nestle HealthCare Nutrition Inc.
$21
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$21
Emmaus Medical, Inc.
$20
Sumitomo Pharma America, Inc.
$19
Mylan Institutional Inc.
$18
Fortovia Therapeutics, Inc.
$18
ImmunoGen, Inc.
$18
Lexicon Pharmaceuticals, Inc.
$18
Novocure Inc.
$17
Helsinn Therapeutics (U.S.), Inc.
$17
Seattle Genetics, Inc.
$17
Array BioPharma Inc.
$15
SERVIER PHARMACEUTICALS LLC
$14
AMAG Pharmaceuticals, Inc.
$13
UCB, Inc.
$13
Top 3 companies account for 25.7% of total payments
Associated products mentioned in payments ›
ABECMA · ADAKVEO · ADCETRIS · AFINITOR · ALIMTA · ALUNBRIG · AVASTIN · AYVAKIT · Abraxane · Alecensa · Aliqopa · Avastin · BALVERSA · BAVENCIO · BENDEKA · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Blincyto · Braftovi · CABLIVI · CALQUENCE · CARVYKTI · CHANTIX · CINVANTI · COSELA · CYRAMZA · Cimzia · Columvi · Copiktra · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELIQUIS · ELITEK · ELREXFIO · EMEND · EMPLICITI · ENHERTU · ENJAYMO · EPKINLY · ERBITUX · ERLEADA · EXKIVITY · Endari · Enhertu · Erleada · FERAHEME · FOTIVDA · FOUNDATIONONE · FRUZAQLA · Fabhalta · Folotyn · GAZYVA · GILOTRIF · HYQVIA · Halaven · IBRANCE · ICLUSIG · IDHIFA · IMBRUVICA · IMFINZI · INFLECTRA · INJECTAFER · INLYTA · INQOVI · INREBIC · Imbruvica · Inrebic · JADENU · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KIMMTRAK · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LONSURF · LORBRENA · LUMAKRAS · LYNPARZA · Lenvima · Lonsurf · Lunsumio · MEKINIST · MONJUVI · MONOFERRIC · MYLOTARG · MYRISK · Monoferric · NERLYNX · NINLARO · Nerlynx · NovoSeven · Novoeight · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OGIVRI · OGSIVEO · OJJAARA · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Onivyde · Optune Lua (NovoTTF-200T) · Orserdu · PADCEV · PIQRAY · PLUVICTO · POLIVY · PROMACTA · PROVENGE · Padcev · Perjeta · Phesgo · Pomalyst · PreciseTumor · Prolia · QINLOCK · Quzyttir · RAYOS · REBLOZYL · RETEVMO · ROLVEDON · RUCONEST · RYBREVANT · RYDAPT · Revlimid · Rezlidhia · Rubraca · SANDOSTATIN · SARCLISA · SCEMBLIX · SIR-Spheres Microspheres · SOMATULINE DEPOT · SPRYCEL · SUTENT · SYNAGIS · Stivarga · TABRECTA · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TEPMETKO · TIBSOVO · TRUSELTIQ · TUKYSA · TUMOR LYSIS SYNDROME - DISEASE · Tavalisse · Tazverik · TheraSphere Y90 Glass Microspheres 10 GBq · Trodelvy · ULTOMIRIS · Udenyca · VENCLEXTA · VERZENIO · VIZIMPRO · VONJO · Vectibix · Venclexta · Vitrakvi · Vonjo · XALKORI · XARELTO · XGEVA · XIFAXAN · XPOVIO · XT CDX · XTANDI · Xermelo · Xospata · Xtandi · Yescarta · ZEJULA · ZENPEP · ZEPZELCA · ZOLADEX · ZYTIGA · Zoladex · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (75%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 6% for optician in TX.
Equivalent to $143 per 100 Medicare services performed
Geographic Context
Opticians within 10 mi
455
Per 100K population
9.6
County median income
$73,104
Nearest hospital
HCA HOUSTON HEALTHCARE NORTHWEST
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Yen is a mixed practice specialist, with above-average Medicare volume (top 2% in TX), and high industry engagement (low-engagement, top 6%), with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Yen experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Yen performed 21,000 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Yen receive payments from pharmaceutical companies?
Yes. Dr. Yen received a total of $40,808 from 106 companies across 1,661 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Yen's costs compare to other opticians in Houston?
Dr. Yen's average Medicare payment per service is $8. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Yen) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Opticians in Houston
Browse opticians in Houston ranked by procedure volume and transparency data.
Highest volume
Top Opticians in TX
Opticians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Opticians in TX
Which TX opticians receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Karyopharm Therapeutics Inc. Payments to Doctors
See all physicians who received payments from Karyopharm Therapeutics Inc..
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology